An ensemble model averaging the predicted probabilities from these four models achieved an AUC of 0.870, outperforming all individual models and the ABCD2 score (AUC, 0.713)
(NYSE: ABBV) is ranked fifth in this report on the strength of its enormous overall pharmaceutical scale and its specific contributions to the peptide therapy market through Lupron (leuprolide acetate) one of the longest-established and most widely prescribed GnRH agonist peptide drugs globally and Botox Therapeutic, whose botulinum toxin A is a functional peptide neurotoxin used across chronic migraine, overactive bladder, spasticity, and cervical dystonia indications
Furthermore, the skin surface is covered by a lipid mantle and exfoliated epidermis
Individuals most likely to benefit include: Those with pernicious anemia People with gastrointestinal disorders (e.g., Crohns disease, celiac disease, chronic gastritis) Patients following bariatric (weight loss) surgery Older adults with absorption difficulties Strict vegetarians or vegans at risk for deficiency People taking medications that can decrease vitamin B12 levels Laboratory testing usually confirms B12 deficiency before starting injections